LQDA Stock Overview
A biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Liquidia Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.14 |
| 52 Week High | US$16.99 |
| 52 Week Low | US$5.82 |
| Beta | 0.22 |
| 11 Month Change | 12.41% |
| 3 Month Change | 0.54% |
| 1 Year Change | 80.70% |
| 33 Year Change | 210.31% |
| 5 Year Change | 139.57% |
| Change since IPO | 0.36% |
Recent News & Updates
Recent updates
Is Liquidia (NASDAQ:LQDA) A Risky Investment?
Jul 18
Broker Revenue Forecasts For Liquidia Corporation (NASDAQ:LQDA) Are Surging Higher
Jan 19Liquidia Corporation's (NASDAQ:LQDA) P/S Still Appears To Be Reasonable
Dec 20Is Liquidia (NASDAQ:LQDA) Using Debt In A Risky Way?
Aug 17Need To Know: Analysts Are Much More Bullish On Liquidia Corporation (NASDAQ:LQDA) Revenues
Mar 18Is Liquidia (NASDAQ:LQDA) Using Too Much Debt?
Feb 06Liquidia (NASDAQ:LQDA) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Oct 25Liquidia: United Manages A Temporary Win
Sep 12Shareholder Returns
| LQDA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.5% | 0.2% | 0.8% |
| 1Y | 80.7% | 23.5% | 38.3% |
Return vs Industry: LQDA exceeded the US Pharmaceuticals industry which returned 23.2% over the past year.
Return vs Market: LQDA exceeded the US Market which returned 36% over the past year.
Price Volatility
| LQDA volatility | |
|---|---|
| LQDA Average Weekly Movement | 11.4% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LQDA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LQDA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 145 | Roger Jeffs | www.liquidia.com |
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion.
Liquidia Corporation Fundamentals Summary
| LQDA fundamental statistics | |
|---|---|
| Market cap | US$966.97m |
| Earnings (TTM) | -US$112.11m |
| Revenue (TTM) | US$14.84m |
63.3x
P/S Ratio-8.4x
P/E RatioIs LQDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LQDA income statement (TTM) | |
|---|---|
| Revenue | US$14.84m |
| Cost of Revenue | US$4.52m |
| Gross Profit | US$10.32m |
| Other Expenses | US$122.43m |
| Earnings | -US$112.11m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.33 |
| Gross Margin | 69.52% |
| Net Profit Margin | -755.46% |
| Debt/Equity Ratio | 137.0% |
How did LQDA perform over the long term?
See historical performance and comparison